FiercePharmaOriginal article
{"a":[{"_":"Bausch + Lomb flops in ph. 2 with Xiidra and Miebo but advances combo to ph. 3","$":{"href":"/pharma/bausch-lomb-flops-ph-2-xiidra-miebo-combo-advances-it-ph-3","hreflang":"en"}}]}
Phase 2negativeXiidraMieboNegative
AI Analysis
Summary
Bausch + Lomb's Phase 2 trial of a Xiidra and Miebo combination for dry eye disease missed its primary endpoint, but the company is advancing the combination to Phase 3 development based on observed promise.
Clinical Trial Data
Phase
2
Primary Endpoint
Not Met
Outcome Details
Phase 2 trial missed primary endpoint but showed sufficient promise to advance combination to Phase 3
Importance:5/10
Sentiment:
-0.30
Phase 2dry eye diseasecombination therapymissed endpoint
Related Companies
Read the original article
Published by FiercePharma on August 25, 2026 10:52 AM